FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Described is a group of inventions comprising mRNA for preventing or treating rabies-related infections, a composition for preparing a medicament for treating or preventing rabies virus infections, a pharmaceutical composition for treating or preventing rabies virus infections, kit for treating or preventing rabies virus infections, using mRNA, a composition, a pharmaceutical composition and a kit as a drug for treating or preventing rabies virus infections and a method of treating or preventing rabies virus infections. In one embodiment, the mRNA comprises a coding region which codes an antigen peptide or protein derived from rabies virus glycoprotein G (RAV-G), or its fragment, variant or derivative and stem-loop histone structure.
EFFECT: invention extends the range of products for preventing or treating rabies virus infections.
33 cl, 21 dwg, 9 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS (RSV) | 2014 |
|
RU2723328C2 |
| CHIMERIC VACCINES BASED ON VIRUSES OF FLAVIVIRUS AND LYSSAVIRUS GENES | 2019 |
|
RU2816136C2 |
| VACCINE AGAINST FELINE CALICIVIRUS | 2018 |
|
RU2792898C2 |
| FRAGMENT OF DNA, CODING SYNTHESIS OF GLYCOPROTEIN OF RABIES G VIRUS, RECOMBINANT PLASMIDAL DNA PVG18-1, CODING GLYCOPROTEIN OF RABIES G VIRUS, ISOLATE OF BACTERIUM EXCHERICHIA COLI IS PRODUCENT OF GLYCOPROTEIN OF RABIES G VIRUS | 1991 |
|
RU2008355C1 |
| POLYVALENT VACCINE FOR CATS | 2018 |
|
RU2797538C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| POLYNUCLEOTIDES ENCODING RELAXIN | 2017 |
|
RU2795683C2 |
| AGENTS FOR THE TREATMENT OF CLAUDINE-EXPRESSING CANCER DISEASES | 2013 |
|
RU2798990C2 |
| FMDV RECOMBINANT VACCINES AND USE THEREOF | 2015 |
|
RU2745373C2 |
| STABILIZED F RSV PROTEINS AND THEIR USE | 2019 |
|
RU2795459C2 |
